Abstract:5-Fluorouracil (5-FU) is a standard chemotherapeutic agent to treat solid cancers such as breast, colon, head, and neck. Computational modeling plays an essential role in predicting the outcome of chemotherapy and developing optimal dosing strategies. We developed an integrated mechanistic pharmacokinetics/pharmacodynamics (PK/PD) model examining the influence of 5-FU, as an S-phase specific double-strand break (DSB)-inducing agent, on tumor proliferation. The proposed mechanistic PK/PD model simulates the dynamics of critical intermediate components and provides the accurate tumor response prediction. The integrated model is composed of PK, cellular, and tumor growth inhibition (TGI) sub-models, quantitatively capturing the essential drug-related physiological processes. In the cellular model, thymidylate synthase (TS) inhibition, resultant deoxynucleoside triphosphate (dNTP) pool imbalance, and DSB induction are considered, as well as 5-FU incorporation into RNA and DNA. The amount of 5-FU anabolites and DSBs were modeled to drive the kinetics of the pharmacological tumor response. Model parameters were estimated by fitting to literature data. Our simulation results successfully describe the kinetics of the intermediates regulating the 5-FU cytotoxic events and the pattern of tumor suppression. The comprehensive model simulated the tumor volume change under various dose regimens, and its generalizability was attested by comparing it with literature data. The potential causes of the tumor resistance to 5-FU are also investigated through Monte Carlo analysis. The simulation of various dosage regimens helps quantify the relationship between treatment protocols and chemotherapy potency, which will lead to the development of efficacy optimization. Computational modeling plays an essential role in predicting the outcome of chemotherapy and developing optimal dosing strategies. In this study, we developed a computational model examining the influence of a chemotherapeutic agent, 5-fluorouracil, on tumor proliferation. 5-fluorouracil is a standard chemotherapeutic agent used to treat solid cancers such as breast, colon, head, and neck. Our model traces the dynamics of critical intermediate components and generates the accurate tumor response prediction in a physiologically-based manner for colon cancer. The comprehensive model simulates the tumor volume change under various dosage regimens, and its generalizability is attested by the validation against literature data. We used the models to investigate potential causes of the tumor resistance to 5-fluorouracil. Our model simulations for various dosage regimens help quantify the relationship between treatment protocols and chemotherapy potency.

Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model

Possible Mechanisms of Acquired Resistance to 5-FU in Human Colon Cancer

Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment after 5-FU and Capecitabine Administration.

A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model

Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update

Expediting the development of robust 5-FU-resistant colorectal cancer models using innovative combined in vivo and in vitro strategies

Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients

Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model

Analyze Impact of Tumor-Associated Kinetics on Antibody Delivery in Solid Tumors with a Physiologically Based Pharmacokinetics/pharmacodynamics Model.

Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy

Determining the Optimal 5-FU Therapeutic Dosage in the Treatment of Colorectal Cancer Patients.

Proteomic Analysis of Differentially Expressed Proteins in 5-Fluorouracil-treated Human Breast Cancer MCF-7 Cells

Multi-omics Analysis Defines 5-Fluorouracil Drug Resistance in 3D HeLa Carcinoma Cell Model

Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience

Cell Cycle Perturbation and Acquired 5-Fluorouracil Chemoresistance

Mechanism-based model for tumor drug resistance

Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response

Resistance to 5-fluorouracil: The molecular mechanisms of development in colon cancer cells

Mitochondrial metabolism is a key determinant of chemotherapy sensitivity in Colorectal Cancer

Research involved with 5-Fu metabolize and resistance mechanism

A Physiologically Based Pharmacokinetic–Pharmacodynamic Model for Capecitabine in Colorectal Cancer Rats: Simulation of Antitumor Efficacy at Various Administration Schedules